- Home
- GALT vs CERT Comparison
GALT vs CERT Comparison
Compare GALT & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- CERT
- Stock Information
- Founded
- GALT 2000
- CERT 2008
- Country
- GALT United States
- CERT United States
- Employees
- GALT N/A
- CERT N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- CERT Retail: Computer Software & Peripheral Equipment
- Sector
- GALT Health Care
- CERT Technology
- Exchange
- GALT Nasdaq
- CERT Nasdaq
- Market Cap
- GALT 147.8M
- CERT 1.9B
- IPO Year
- GALT N/A
- CERT 2020
- Fundamental
- Price
- GALT $1.04
- CERT $10.71
- Analyst Decision
- GALT Strong Buy
- CERT Buy
- Analyst Count
- GALT 1
- CERT 7
- Target Price
- GALT $11.00
- CERT $15.92
- AVG Volume (30 Days)
- GALT 1.1M
- CERT 1.5M
- Earning Date
- GALT 11-13-2024
- CERT 11-06-2024
- Dividend Yield
- GALT N/A
- CERT N/A
- EPS Growth
- GALT N/A
- CERT N/A
- EPS
- GALT N/A
- CERT N/A
- Revenue
- GALT N/A
- CERT $372,797,000.00
- Revenue This Year
- GALT N/A
- CERT $10.20
- Revenue Next Year
- GALT N/A
- CERT $10.01
- P/E Ratio
- GALT N/A
- CERT N/A
- Revenue Growth
- GALT N/A
- CERT 5.62
- 52 Week Low
- GALT $0.73
- CERT $9.41
- 52 Week High
- GALT $4.27
- CERT $19.87
- Technical
- Relative Strength Index (RSI)
- GALT 20.80
- CERT 45.72
- Support Level
- GALT $1.80
- CERT $10.31
- Resistance Level
- GALT $2.36
- CERT $11.77
- Average True Range (ATR)
- GALT 0.27
- CERT 0.58
- MACD
- GALT -0.08
- CERT -0.07
- Stochastic Oscillator
- GALT 15.07
- CERT 26.32
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.